Verve Therapeutics 根据其 2024 年诱导性股票激励计划向新员工授予股权奖励，包括 76,900 股股票期权和 19,200 股 RSU。 Verve Therapeutics grants equity awards, including 76,900 stock options and 19,200 RSUs, to new employee under its 2024 Inducement Stock Incentive Plan.
Verve Therapeutics 是一家临床阶段的生物科技公司，致力于开发用于治疗心血管疾病的基因编辑药物。根据公司 2024 年诱导性股票激励计划，该公司向一名新员工授予了股权奖励，包括 76,900 股股票期权和 19,200 股 RSU。 Verve Therapeutics, a clinical-stage biotech company developing gene editing medicines for cardiovascular diseases, granted equity awards to a new employee, including a stock option for 76,900 shares and 19,200 RSUs, under the company's 2024 Inducement Stock Incentive Plan. 股票期权期限为 10 年，在 4 年内归属，而 RSU 在 4 年内每年归属一次，取决于员工是否继续服务。 The stock option, with a 10-year term, vests over four years, while the RSUs vest annually over four years, contingent on the employee's continued service.